CR Double-Crane(SH:600062) Shang Hai Zheng Quan Bao·2026-02-10 19:17Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has announced that several of its drugs are expected to be selected in the continuation procurement organized by the National Organization for Drug Procurement, which is set to stabilize or further reduce prices while enhancing the selection power of medical institutions [1][4]. Group 1: Selected Drugs - The company participated in the continuation procurement for drugs whose agreements have expired, with several key products expected to be selected, including those that rank among the top five in revenue [1][2]. - The procurement cycle for the selected drugs will last until December 31, 2028 [1]. Group 2: Financial Impact - In 2024, the sales revenue for Valsartan Hydrochlorothiazide Tablets is projected to be 517 million yuan, accounting for 4.61% of the total revenue; for Nifedipine Controlled-Release Tablets, it is expected to be 147 million yuan, or 1.31% [3]. - For the first three quarters of 2025, the sales revenue for Valsartan Hydrochlorothiazide Tablets is estimated at 426 million yuan, representing 5.14% of total revenue; for Nifedipine Controlled-Release Tablets, it is projected at 138 million yuan, or 1.67% [3]. Group 3: Market Dynamics - The continuation procurement is expected to maintain price stability or further decrease prices, allowing medical institutions greater choice among selected suppliers, which may help ensure continuity in clinical medication and reduce risks associated with drug switching [4]. - Although the selection may lead to a decrease in overall sales revenue, it is anticipated that the company can solidify its existing market share and potentially increase its market penetration due to its brand influence and reliable supply capabilities [4].